Risk Management Resources for Gaucher Disease Therapy
Long-term monitoring is a core component of managing patients on enzyme replacement therapy for Gaucher disease. This page provides risk management programme materials that support healthcare professionals in tracking treatment response, infusion-related reactions and disease progression markers. Structured monitoring helps ensure that therapeutic goals for bone, haematological and visceral disease are being met over time. Materials are intended to complement, not replace, individual clinical judgement.
HCP Guide
CEREZYME® 400 HOME INFUSION:
A guide for Healthcare Professionals treating patients with Gaucher Disease
Patient Guide
A guide for patients with Gaucher Disease who are prescribed and receive home infusion of Cerezyme 400.
Information to be shared with patients before commencing home infusion therapy.
Patient Reconstitution Guide
Cerezyme Preparation and Administration Guide to Share with Your Patient
Cerezyme Reconstitution Video:
View the video on how to reconstitute and prepare infusion of Cerezyme
Have any medical information inquiries?
Please email za.medinfo@sanofi.com for any medical information inquiries.
Gaucher disease requires long-term monitoring of haematological parameters, organ volumes and skeletal involvement to confirm that treatment is achieving expected therapeutic goals. Structured monitoring frameworks help detect suboptimal response or disease progression early. This supports timely discussion of dose adjustment or further investigation where required. Consistent monitoring also supports long-term safety surveillance for patients on enzyme replacement therapy.
Routine monitoring typically includes haemoglobin, platelet count, liver and spleen volume, and skeletal assessment through imaging where indicated. Infusion-related reactions should also be documented as part of ongoing safety monitoring. Monitoring frequency is generally more intensive at treatment initiation and can be adjusted as the patient stabilises. These parameters help guide any need for dose modification over time.
Registered healthcare professionals can access the risk management programme materials directly through this platform after login. These materials are designed to support consistent monitoring practice across treating clinicians. Access may require confirmation of prescribing or treating status for patients with Gaucher disease. Materials are updated periodically to reflect current monitoring recommendations.
Confirm that you are a healthcare professional to continue reading.
Click login to continue